Advertisement
U.S. markets open in 8 hours 25 minutes
  • S&P Futures

    5,209.50
    -5.25 (-0.10%)
     
  • Dow Futures

    39,214.00
    -9.00 (-0.02%)
     
  • Nasdaq Futures

    18,184.75
    -46.75 (-0.26%)
     
  • Russell 2000 Futures

    2,048.30
    -1.50 (-0.07%)
     
  • Crude Oil

    82.59
    -0.13 (-0.16%)
     
  • Gold

    2,163.20
    -1.10 (-0.05%)
     
  • Silver

    25.30
    +0.03 (+0.14%)
     
  • EUR/USD

    1.0872
    -0.0005 (-0.04%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2717
    -0.0011 (-0.09%)
     
  • USD/JPY

    150.1190
    +1.0210 (+0.68%)
     
  • Bitcoin USD

    65,513.82
    -2,705.44 (-3.97%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,823.35
    +82.95 (+0.21%)
     

PerkinElmer Sells Prenatal Screening Lab Services Unit To Eurofins Scientific

PerkinElmer, Inc. (NYSE: PKI) disclosed it sold its prenatal screening laboratory services unit, PerkinElmer Labs/NTD in the United States To Eurofins Scientific. Terms and conditions of the financial details were not disclosed.

According to the company, NTD generated about $20 million in revenue in 2015. The company believes there would not be any significant financial impact due to the divestiture, and that it would not have any material impact on its 2016 earnings per share guidance, which was offered on February 4.

PerkinElmer President for Diagnostics, Prahlad Singh, said "Recent changes to U.S. healthcare reform continue to drive the consolidation of diagnostics testing towards broader service providers. Eurofins, with its breadth of testing services and capabilities, is uniquely positioned to meet the expanding service needs of NTD's customers."

He added, "Furthermore, the divestiture of the NTD business allows PerkinElmer to concentrate its efforts on developing innovative maternal fetal health technologies and solutions for the U.S. Outside the U.S., we will continue to provide kits, technologies and services through a variety of channels focused on improving health outcomes for babies and expectant mothers."

On Friday, the closed gained 0.33 percent.

See more from Benzinga

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement